Get the Stockscreener App
13.10
0.65%
-0.0666
Aurinia Pharmaceuticals Inc stock is traded at $13.10, with a volume of 2.36M.
It is down -0.65% in the last 24 hours and up +15.29% over the past month.
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
See More
Previous Close:
$13.17
Open:
$13.1
24h Volume:
2.36M
Relative Volume:
1.26
Market Cap:
$1.72B
Revenue:
$260.11M
Net Income/Loss:
$60.64M
P/E Ratio:
30.47
EPS:
0.43
Net Cash Flow:
$92.29M
1W Performance:
+6.47%
1M Performance:
+15.29%
6M Performance:
+59.38%
1Y Performance:
+78.76%
1-Day Range:
$12.79
$13.49
1-Week Range:
$11.96
$13.49
52-Week Range:
$6.55
$13.54
Aurinia Pharmaceuticals Inc Stock (AUPH) Company Profile
Name
Aurinia Pharmaceuticals Inc
Sector
Industry
Phone
250-744-2487
Address
#140, 14315 - 118 AVENUE, EDMONTON, BC
Compare AUPH with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AUPH
Aurinia Pharmaceuticals Inc
|
13.09 | 1.73B | 260.11M | 60.64M | 92.29M | 0.43 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.69 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
641.80 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.61 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
822.11 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
183.82 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Aurinia Pharmaceuticals Inc Stock (AUPH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-30-25 | Resumed | H.C. Wainwright | Buy |
| Nov-04-22 | Downgrade | Oppenheimer | Outperform → Perform |
| May-05-22 | Resumed | Cantor Fitzgerald | Overweight |
| Dec-10-21 | Upgrade | Oppenheimer | Perform → Outperform |
| Oct-28-21 | Downgrade | Oppenheimer | Outperform → Perform |
| Jan-25-21 | Reiterated | H.C. Wainwright | Buy |
| Nov-03-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-17-20 | Initiated | BTIG Research | Buy |
| May-05-20 | Initiated | Cowen | Outperform |
| Jan-10-20 | Initiated | Jefferies | Buy |
| Dec-16-19 | Reiterated | H.C. Wainwright | Buy |
| Mar-16-18 | Reiterated | Cantor Fitzgerald | Overweight |
| Feb-08-18 | Initiated | RBC Capital Mkts | Outperform |
| Oct-30-17 | Reiterated | H.C. Wainwright | Buy |
| May-18-17 | Reiterated | H.C. Wainwright | Buy |
| Apr-11-17 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-22-17 | Reiterated | FBR & Co. | Outperform |
| Dec-30-16 | Reiterated | H.C. Wainwright | Buy |
| Aug-17-16 | Reiterated | H.C. Wainwright | Buy |
| Jun-30-16 | Initiated | H.C. Wainwright | Buy |
| May-08-15 | Initiated | MLV & Co | Buy |
View All
Aurinia Pharmaceuticals Inc Stock (AUPH) Latest News
Aurinia Pharmaceuticals Reportedly Files Lawsuit Against US FDA Official - MarketScreener
Is Aurinia Pharmaceuticals Inc. stock positioned well for digital economyTrade Exit Summary & Stepwise Swing Trade Plans - newser.com
FDA’s Top Drug Regulator Resigns, Agency Cites Personal Conduct - Bloomberg.com
Strategies to average down on Aurinia Pharmaceuticals Inc.2025 Analyst Calls & Consistent Growth Equity Picks - newser.com
Will Aurinia Pharmaceuticals Inc. stock recover faster than marketGlobal Markets & Weekly Stock Breakout Alerts - newser.com
Aurinia Pharmaceuticals Inc expected to post earnings of 16 cents a shareEarnings Preview - TradingView
Wall Street Breakfast Podcast: FDA Executive Controversy (undefined:AUPH) - Seeking Alpha
Aurinia Pharmaceuticals to Report Financial Results for the Three and Nine Months Ended September 30, 2025 and Provide Update on Recent Business Progress on November 4, 2025 - Business Wire
Aurinia Pharmaceuticals To Report Q3 Results, Provide Update On Recent Business Progress On November 4 - TradingView
Can Aurinia Pharmaceuticals Inc. stock reach $100 price targetRecession Risk & Low Drawdown Investment Ideas - newser.com
PRESS DIGEST-Wall Street JournalNovember 3 - facilitiesmanagement-now.com
Analyzing drawdowns of Aurinia Pharmaceuticals Inc. with statistical toolsWeekly Trend Summary & Long-Term Capital Growth Ideas - newser.com
Is Aurinia Pharmaceuticals Inc. reversing from oversold territoryMarket Movement Recap & Free Weekly Watchlist of Top Performers - newser.com
Combining price and volume data for Aurinia Pharmaceuticals Inc.Weekly Trading Summary & Daily Profit Focused Stock Screening - newser.com
Key metrics from Aurinia Pharmaceuticals Inc.’s quarterly dataTreasury Yields & Daily Chart Pattern Signal Reports - newser.com
F.D.A. Drug Unit Chief Resigns, and Is Sued by Drug Company - The New York Times
Top FDA official Tidmarsh resigns after comments on kidney drug, HHS probe - Seeking Alpha
FDA Turmoil Spills Over To Aurinia Pharma As Lawsuit Targets Ex-Drug Review Chief — Retail Traders Cry ‘Stock Manipulation’ - Stocktwits
Is Aurinia Pharmaceuticals Inc. (IKAP) stock undervalued historicallyMarket Growth Summary & Free High Return Stock Watch Alerts - newser.com
FDA Official Steps Down, Sued by Drugmaker - The Wall Street Journal
Will breakout in Aurinia Pharmaceuticals Inc. lead to full recoveryWeekly Earnings Recap & Free Expert Approved Momentum Trade Ideas - newser.com
What analysts say about Aurinia Pharmaceuticals Inc IKAP stockMACD Trading Signals & Double Digit Wealth Tips - earlytimes.in
Visualizing Aurinia Pharmaceuticals Inc. stock with heatmaps2025 Momentum Check & Safe Investment Capital Preservation Plans - newser.com
Chart overlay techniques for tracking Aurinia Pharmaceuticals Inc.Market Performance Summary & Community Consensus Picks - newser.com
Why Aurinia Pharmaceuticals Inc. is moving todayEarnings Overview Report & Real-Time Buy Zone Alerts - newser.com
Using R and stats models for Aurinia Pharmaceuticals Inc. forecastingProfit Target & Weekly Market Pulse Alerts - newser.com
Is There An Opportunity With Aurinia Pharmaceuticals Inc.'s (NASDAQ:AUPH) 49% Undervaluation? - Yahoo Finance
Aurinia Pharmaceuticals (AUPH) Expected to Announce Quarterly Earnings on Thursday - MarketBeat
Using data models to predict Aurinia Pharmaceuticals Inc. stock movementJuly 2025 Intraday Action & Long-Term Safe Investment Plans - newser.com
Is Aurinia Pharmaceuticals Inc. building a consolidation baseMarket Volume Report & High Accuracy Trade Signal Alerts - newser.com
Is Aurinia Pharmaceuticals Inc. (IKAP) stock a good hedge against inflation2025 Biggest Moves & AI Powered Buy and Sell Recommendations - newser.com
Aurinia Pharmaceuticals Inc Stock (AUPH) Financials Data
Revenue
Net Income
Cash Flow
EPS
Aurinia Pharmaceuticals Inc Stock (AUPH) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| TANG KEVIN | Director |
Aug 05 '25 |
Buy |
11.68 |
200,000 |
2,336,000 |
11,329,500 |
| TANG KEVIN | Director |
Aug 04 '25 |
Buy |
11.34 |
100,000 |
1,134,000 |
11,129,500 |
| Keenan Greg | Chief Medical Officer |
Aug 01 '25 |
Sale |
10.50 |
20,000 |
210,000 |
133,484 |
| Keenan Greg | Chief Medical Officer |
Mar 07 '25 |
Sale |
8.23 |
8,305 |
68,350 |
153,484 |
| Greenleaf Peter | Chief Executive Officer |
Mar 03 '25 |
Sale |
8.00 |
195,593 |
1,564,744 |
1,953,892 |
| Greenleaf Peter | Chief Executive Officer |
Mar 04 '25 |
Sale |
7.92 |
164,947 |
1,306,380 |
1,788,945 |
| Keenan Greg | Chief Medical Officer |
Mar 03 '25 |
Sale |
8.00 |
12,239 |
97,912 |
161,789 |
| Miller Joseph M | Chief Financial Officer |
Mar 03 '25 |
Sale |
8.00 |
61,859 |
494,872 |
633,515 |
| Miller Joseph M | Chief Financial Officer |
Mar 04 '25 |
Sale |
7.92 |
56,154 |
444,740 |
577,361 |
| Robertson Stephen P. | EVP, General Counsel |
Mar 03 '25 |
Sale |
8.00 |
64,872 |
518,976 |
566,883 |
0.29%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):